Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective Study of Lanadelumab Prophylaxis in Chinese Hereditary Angioedema Patients
ChiCTR2500098307Phase 4Recruiting
- Sponsor
- Renji Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lanadelumab in hereditary angioedema (HAE), sponsored by Renji Hospital. Primary endpoint: Attacks of angioedema. Started Mar 2025; status: recruiting.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on ChiCTR2500098307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098307.